US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ATYR PHARMA INC

0.5176

+0.01613.21%

Volume:517.54K

Turnover:263.69K

Market Cap:50.72M

PE:-0.83

High:0.5340

Open:0.5106

Low:0.4900

Close:0.5015

52wk High:6.50

52wk Low:0.3950

Shares:97.99M

Float Shares:95.97M

Volume Ratio:1.05

T/O Rate:0.54%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.6214

EPS(LYR):-0.7971

ROE:-98.68%

ROA:-46.58%

PB:1.04

PE(LYR):-0.65

Loading ...

Overview Company News Filings

aTyr Pharma wins Nasdaq extension to regain $1 minimum bid price compliance by Nov. 30

Phase 3 Efzofitimod Readout Nears: What ATYR Investors Should Watch in Pulmonary Sarcoidosis

aTyr Pharma director Paul Schimmel acquires 100,000 common shares valued at $49,630

aTyr Pharma Raised to Buy From Hold by Freedom Broker

aTyr Pharma upgraded to Buy from Hold at Freedom Broker

RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)

Wells Fargo Sticks to Their Hold Rating for aTyr Pharma (ATYR)

aTyr Pharma Inc options imply 30.5% move in share price post-earnings

aTyr Pharma Inc reports results for the quarter ended March 31 - Earnings Summary

aTyr Pharma Q1 EPS $(0.11) Beats $(0.14) Estimate

Benzinga Earnings

aTyr Pharma plans Phase 3 efzofitimod trial in restrictive pulmonary sarcoidosis

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

THOMSON REUTERS

aTyr Pharma plans Phase 3 pulmonary sarcoidosis trial of efzofitimod with FVC endpoint

Calendar of U.S. Earnings Expected in the Week Ahead

Piper Sandler Sticks to Their Buy Rating for aTyr Pharma (ATYR)

aTyr Pharma plans June 2026 IND for new Phase 3 efzofitimod sarcoidosis trial

aTyr Pharma Inc - Primary Endpoint Will Be Change in Fvc at Week 48; Key Secondary Endpoint Will Be Change From Baseline in Ksq-Lung Score

THOMSON REUTERS

aTyr Pharma Inc - Dosing Frequency of 5.0 Mg/Kg Efzofitimod or Placebo Increased to Every Three Weeks in Next Phase 3 Trial

THOMSON REUTERS

aTyr Pharma Inc: to Continue Development of Efzofitimod in Pulmonary Sarcoidosis Incorporating FDA Feedback

THOMSON REUTERS

aTyr Pharma Inc options imply 14.1% move in share price post-earnings

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/ATYR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATYR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATYR\",,,,,undefined,":{"symbol":"ATYR","market":"US","secType":"STK","nameCN":"ATYR PHARMA INC","latestPrice":0.5176,"timestamp":1787596285819,"preClose":0.5015,"halted":0,"volume":517535,"delay":0,"changeRate":0.03210368893320041,"floatShares":95966000,"shares":97986634,"eps":-0.621383,"marketStatus":"Trading","change":0.0161,"latestTime":"08-24 14:31:25 EDT","open":0.5106,"high":0.534,"low":0.49,"amount":263692.984102,"amplitude":0.087737,"askPrice":0.5231,"askSize":30,"bidPrice":0.512,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.621383,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"listingDate":1430971200000,"exchange":"NASDAQ","adjPreClose":0.5015,"preHourTrading":{"tag":"盘前","latestPrice":0.52,"preClose":0.5015,"latestTime":"08:56 EDT","volume":11918,"amount":6159.44240628,"timestamp":1787576178374,"change":0.0185,"changeRate":0.036889,"amplitude":0.034696},"postHourTrading":{"tag":"盘后","latestPrice":0.525,"preClose":0.5015,"latestTime":"19:30 EDT","volume":22277,"amount":11180.83,"timestamp":1787355005341,"change":0.0235,"changeRate":0.046859,"amplitude":0.046859},"volumeRatio":1.045916,"impliedVol":1.3058,"impliedVolPercentile":0.3825},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATYR\",,,,,undefined,":{"symbol":"ATYR","floatShares":95966000,"roa":"-46.58%","roe":"-98.68%","lyrEps":-0.797093,"volumeRatio":1.045916,"shares":97986634,"dividePrice":0,"high":0.534,"amplitude":0.087737,"preClose":0.5015,"low":0.49,"week52Low":0.395,"pbRate":"1.04","psRate":"266.94","week52High":6.5,"institutionHeld":0,"latestPrice":0.5176,"committee":0.538462,"eps":-0.621383,"divideRate":0,"volume":517535,"delay":0,"ttmEps":-0.621383,"open":0.5106,"prevYearClose":0.7831,"prevWeekClose":0.5015,"prevMonthClose":0.4857,"prevQuarterClose":0.5968,"fiveDayClose":0.5189,"twentyDayClose":0.4896,"sixtyDayClose":0.4874},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATYR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"ATYR","fiscalQuarterEnding":"2026/06","expectedEps":-0.15,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"post","actualEps":-0.11},{"market":"US","date":"2026-05-15","symbol":"ATYR","fiscalQuarterEnding":"2026/03","expectedEps":-0.16,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-0.11},{"market":"US","date":"2026-03-05","symbol":"ATYR","fiscalQuarterEnding":"2025/12","expectedEps":-0.18,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-0.14},{"market":"US","date":"2025-11-06","symbol":"ATYR","fiscalQuarterEnding":"2025/09","expectedEps":-0.2,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.26},{"market":"US","date":"2025-08-07","symbol":"ATYR","fiscalQuarterEnding":"2025/06","expectedEps":-0.18,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":-0.22}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATYR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATYR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.3333,"hold":0.5556,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":9,"updateTime":1779336000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ATYR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ATYR","date":"2026-08-21","current":-0.808519,"percent":0.902439,"low":-9.277729,"twenty":-4.943205,"median":-2.373775,"eighty":-0.980779,"high":-0.523739,"avg":-3.112398,"sd":2.33393,"marketCap":49337974},"quantilePoints":[{"date":"2024-06-07","current":-2.380173,"twenty":-2.380173,"median":-2.380173,"eighty":-2.380173,"marketCap":128360348},{"date":"2024-06-14","current":-2.367376,"twenty":-2.482546,"median":-2.431359,"eighty":-2.377614,"marketCap":127670239},{"date":"2024-06-21","current":-2.021867,"twenty":-2.446715,"median":-2.367376,"eighty":-2.203579,"marketCap":109037285},{"date":"2024-06-28","current":-1.970681,"twenty":-2.431359,"median":-2.367376,"eighty":-2.111444,"marketCap":106276847},{"date":"2024-07-05","current":-1.970681,"twenty":-2.431359,"median":-2.265003,"eighty":-1.991155,"marketCap":106276847},{"date":"2024-07-12","current":-2.073054,"twenty":-2.39041,"median":-2.092249,"eighty":-1.970681,"marketCap":111797722},{"date":"2024-07-15","current":-2.226613,"twenty":-2.380173,"median":-2.111444,"eighty":-1.970681,"marketCap":120079035},{"date":"2024-08-02","current":-2.495343,"twenty":-2.421122,"median":-2.130639,"eighty":-1.9758,"marketCap":134571333},{"date":"2024-08-09","current":-2.380173,"twenty":-2.403207,"median":-2.265003,"eighty":-1.996274,"marketCap":128360348},{"date":"2024-08-16","current":-2.618312,"twenty":-2.418704,"median":-2.296995,"eighty":-2.001393,"marketCap":151592396},{"date":"2024-08-23","current":-2.448121,"twenty":-2.445503,"median":-2.341783,"eighty":-2.021867,"marketCap":141738890},{"date":"2024-08-30","current":-2.474305,"twenty":-2.468042,"median":-2.373775,"eighty":-2.032104,"marketCap":143254814},{"date":"2024-09-06","current":-2.291023,"twenty":-2.461213,"median":-2.354579,"eighty":-2.073054,"marketCap":132643346},{"date":"2024-09-13","current":-2.448121,"twenty":-2.474305,"median":-2.380173,"eighty":-2.111444,"marketCap":141738890},{"date":"2024-09-20","current":-2.448121,"twenty":-2.474305,"median":-2.399368,"eighty":-2.149834,"marketCap":141738890},{"date":"2024-09-27","current":-2.277931,"twenty":-2.474305,"median":-2.382664,"eighty":-2.226613,"marketCap":131885384},{"date":"2024-10-04","current":-2.277931,"twenty":-2.469749,"median":-2.373775,"eighty":-2.226613,"marketCap":131885384},{"date":"2024-10-11","current":-2.77541,"twenty":-2.474305,"median":-2.382664,"eighty":-2.251748,"marketCap":160687939},{"date":"2024-10-18","current":-3.469263,"twenty":-2.48085,"median":-2.399368,"eighty":-2.251748,"marketCap":200859924},{"date":"2024-10-25","current":-4.241665,"twenty":-2.500488,"median":-2.421938,"eighty":-2.265003,"marketCap":245579681},{"date":"2024-10-31","current":-4.097658,"twenty":-2.555472,"median":-2.431359,"eighty":-2.275241,"marketCap":237242099},{"date":"2024-11-08","current":-4.058383,"twenty":-2.922036,"median":-2.441575,"eighty":-2.277905,"marketCap":234968213},{"date":"2024-11-15","current":-3.78886,"twenty":-3.621287,"median":-2.448121,"eighty":-2.277931,"marketCap":241789871},{"date":"2024-11-22","current":-3.919838,"twenty":-3.629704,"median":-2.448121,"eighty":-2.277931,"marketCap":250148372},{"date":"2024-11-29","current":-4.643298,"twenty":-3.916561,"median":-2.461213,"eighty":-2.285786,"marketCap":296316696},{"date":"2024-12-06","current":-4.301299,"twenty":-4.007344,"median":-2.474305,"eighty":-2.298878,"marketCap":274491670},{"date":"2024-12-13","current":-3.972453,"twenty":-4.100191,"median":-2.474305,"eighty":-2.31136,"marketCap":253506069},{"date":"2024-12-20","current":-4.143453,"twenty":-4.111931,"median":-2.474305,"eighty":-2.3168,"marketCap":264418582},{"date":"2024-12-27","current":-4.95899,"twenty":-4.144489,"median":-2.487396,"eighty":-2.317206,"marketCap":316462874},{"date":"2025-01-03","current":-5.143143,"twenty":-4.229494,"median":-2.500488,"eighty":-2.317206,"marketCap":328214811},{"date":"2025-01-10","current":-4.919528,"twenty":-4.267848,"median":-2.526671,"eighty":-2.317206,"marketCap":313944602},{"date":"2025-01-17","current":-4.932682,"twenty":-4.327606,"median":-2.579037,"eighty":-2.328986,"marketCap":314784026},{"date":"2025-01-24","current":-4.682759,"twenty":-4.341161,"median":-2.768865,"eighty":-2.330035,"marketCap":298834968},{"date":"2025-01-31","current":-4.919528,"twenty":-4.389843,"median":-2.932509,"eighty":-2.330297,"marketCap":313944602},{"date":"2025-02-07","current":-5.090528,"twenty":-4.509129,"median":-3.510289,"eighty":-2.339486,"marketCap":324857115},{"date":"2025-02-14","current":-4.722221,"twenty":-4.606467,"median":-3.575068,"eighty":-2.341783,"marketCap":301353241},{"date":"2025-02-21","current":-5.827142,"twenty":-4.643298,"median":-3.6107,"eighty":-2.357139,"marketCap":371864863},{"date":"2025-02-28","current":-5.090528,"twenty":-4.682759,"median":-3.851618,"eighty":-2.375054,"marketCap":324857115},{"date":"2025-03-07","current":-4.051376,"twenty":-4.682759,"median":-3.972453,"eighty":-2.380173,"marketCap":258542613},{"date":"2025-03-14","current":-5.248373,"twenty":-4.682759,"median":-3.985607,"eighty":-2.381668,"marketCap":334930203},{"date":"2025-03-21","current":-4.929845,"twenty":-4.727483,"median":-3.990774,"eighty":-2.382664,"marketCap":315623450},{"date":"2025-03-28","current":-4.52461,"twenty":-4.75379,"median":-4.035211,"eighty":-2.388848,"marketCap":289679075},{"date":"2025-04-04","current":-3.872289,"twenty":-4.740636,"median":-4.038222,"eighty":-2.400648,"marketCap":247915527},{"date":"2025-04-11","current":-3.802893,"twenty":-4.727483,"median":-4.011134,"eighty":-2.407615,"marketCap":243472596},{"date":"2025-04-17","current":-4.191509,"twenty":-4.722221,"median":-4.035211,"eighty":-2.414083,"marketCap":268353008},{"date":"2025-04-25","current":-4.788314,"twenty":-4.743267,"median":-4.051376,"eighty":-2.421938,"marketCap":306562211},{"date":"2025-05-02","current":-4.635643,"twenty":-4.743267,"median":-4.087671,"eighty":-2.425706,"marketCap":296787764},{"date":"2025-05-09","current":-4.680309,"twenty":-4.75642,"median":-4.108234,"eighty":-2.431359,"marketCap":296787764},{"date":"2025-05-16","current":-4.210769,"twenty":-4.743267,"median":-4.133647,"eighty":-2.432827,"marketCap":267013308},{"date":"2025-05-23","current":-5.333641,"twenty":-4.774836,"median":-4.143453,"eighty":-2.440266,"marketCap":338216856},{"date":"2025-05-30","current":-5.972275,"twenty":-4.816072,"median":-4.149872,"eighty":-2.448121,"marketCap":378713875},{"date":"2025-06-06","current":-7.509205,"twenty":-4.87282,"median":-4.17922,"eighty":-2.448121,"marketCap":476173732},{"date":"2025-06-13","current":-7.621493,"twenty":-4.919528,"median":-4.191509,"eighty":-2.448121,"marketCap":483294087},{"date":"2025-06-20","current":-7.256559,"twenty":-4.932682,"median":-4.241665,"eighty":-2.448121,"marketCap":460152934},{"date":"2025-06-27","current":-7.453062,"twenty":-4.985297,"median":-4.254757,"eighty":-2.448121,"marketCap":472613555},{"date":"2025-07-03","current":-7.453062,"twenty":-5.016231,"median":-4.28094,"eighty":-2.448121,"marketCap":472613555},{"date":"2025-07-11","current":-7.481134,"twenty":-5.080005,"median":-4.302543,"eighty":-2.458595,"marketCap":474393643},{"date":"2025-07-18","current":-8.126785,"twenty":-5.119466,"median":-4.327606,"eighty":-2.461213,"marketCap":515335684},{"date":"2025-07-25","current":-7.796941,"twenty":-5.18655,"median":-4.339852,"eighty":-2.468042,"marketCap":494419641},{"date":"2025-08-01","current":-6.624944,"twenty":-5.237851,"median":-4.345289,"eighty":-2.473394,"marketCap":420100937},{"date":"2025-08-08","current":-7.354811,"twenty":-5.277498,"median":-4.380221,"eighty":-2.474305,"marketCap":466383244},{"date":"2025-08-15","current":-7.337565,"twenty":-5.711388,"median":-4.396173,"eighty":-2.474305,"marketCap":488953303},{"date":"2025-08-22","current":-7.278747,"twenty":-6.338611,"median":-4.472298,"eighty":-2.474305,"marketCap":485033838},{"date":"2025-08-29","current":-7.866928,"twenty":-6.868599,"median":-4.491152,"eighty":-2.474305,"marketCap":524228491},{"date":"2025-09-05","current":-8.043383,"twenty":-7.051635,"median":-4.498606,"eighty":-2.474305,"marketCap":535986887},{"date":"2025-09-12","current":-7.734587,"twenty":-7.202339,"median":-4.538489,"eighty":-2.478232,"marketCap":515409694},{"date":"2025-09-19","current":-1.543977,"twenty":-7.202339,"median":-4.511608,"eighty":-2.474305,"marketCap":102885965},{"date":"2025-09-26","current":-1.313556,"twenty":-7.183573,"median":-4.496851,"eighty":-2.466335,"marketCap":87531460},{"date":"2025-10-03","current":-1.043875,"twenty":-7.138658,"median":-4.477635,"eighty":-2.448121,"marketCap":69560711},{"date":"2025-10-10","current":-1.401343,"twenty":-7.082514,"median":-4.406529,"eighty":-2.442885,"marketCap":93381262},{"date":"2025-10-17","current":-1.470454,"twenty":-7.051635,"median":-4.382946,"eighty":-2.421938,"marketCap":97986634},{"date":"2025-10-24","current":-1.430458,"twenty":-7.012335,"median":-4.346398,"eighty":-2.388848,"marketCap":95321397},{"date":"2025-10-31","current":-1.305763,"twenty":-6.956191,"median":-4.340306,"eighty":-2.375054,"marketCap":87012130},{"date":"2025-11-07","current":-1.004754,"twenty":-6.884883,"median":-4.327606,"eighty":-2.330297,"marketCap":75479104},{"date":"2025-11-14","current":-0.930535,"twenty":-6.741157,"median":-4.315074,"eighty":-2.317206,"marketCap":69903664},{"date":"2025-11-21","current":-0.849664,"twenty":-6.641787,"median":-4.294031,"eighty":-2.285786,"marketCap":63828493},{"date":"2025-11-28","current":-1.018058,"twenty":-6.613715,"median":-4.254757,"eighty":-2.277852,"marketCap":76478567},{"date":"2025-12-05","current":-1.079755,"twenty":-6.467742,"median":-4.247271,"eighty":-2.236667,"marketCap":81113335},{"date":"2025-12-12","current":-0.998232,"twenty":-6.153338,"median":-4.191509,"eighty":-2.08841,"marketCap":74989171},{"date":"2025-12-19","current":-0.9171,"twenty":-5.941396,"median":-4.17922,"eighty":-1.996274,"marketCap":68894402},{"date":"2025-12-26","current":-0.962753,"twenty":-5.88149,"median":-4.159816,"eighty":-1.970681,"marketCap":72323934},{"date":"2026-01-02","current":-1.02145,"twenty":-5.827142,"median":-4.144316,"eighty":-1.58809,"marketCap":76733333},{"date":"2026-01-09","current":-0.945796,"twenty":-5.68245,"median":-4.143453,"eighty":-1.529272,"marketCap":71050108},{"date":"2026-01-16","current":-0.921535,"twenty":-5.590373,"median":-4.115174,"eighty":-1.499863,"marketCap":69227556},{"date":"2026-01-23","current":-0.973579,"twenty":-5.463588,"median":-4.100824,"eighty":-1.470454,"marketCap":73137223},{"date":"2026-01-30","current":-1.109494,"twenty":-5.353291,"median":-4.058383,"eighty":-1.430928,"marketCap":83347430},{"date":"2026-02-06","current":-1.05745,"twenty":-5.277498,"median":-4.044799,"eighty":-1.420105,"marketCap":79437764},{"date":"2026-02-13","current":-1.16206,"twenty":-5.263462,"median":-4.025068,"eighty":-1.381433,"marketCap":87296292},{"date":"2026-02-20","current":-1.369585,"twenty":-5.259961,"median":-3.990774,"eighty":-1.302178,"marketCap":102885965},{"date":"2026-02-27","current":-1.291323,"twenty":-5.252075,"median":-3.985607,"eighty":-1.296092,"marketCap":97006767},{"date":"2026-03-06","current":-1.193659,"twenty":-5.240481,"median":-3.979834,"eighty":-1.286732,"marketCap":88471608},{"date":"2026-03-13","current":-1.147622,"twenty":-5.227328,"median":-3.937701,"eighty":-1.255818,"marketCap":85059426},{"date":"2026-03-20","current":-1.094838,"twenty":-5.211936,"median":-3.872289,"eighty":-1.237152,"marketCap":81147183},{"date":"2026-03-27","current":-1.048668,"twenty":-5.203474,"median":-3.781997,"eighty":-1.214301,"marketCap":77725195},{"date":"2026-04-02","current":-1.125529,"twenty":-5.194443,"median":-3.671031,"eighty":-1.194857,"marketCap":83421971},{"date":"2026-04-10","current":-0.99218,"twenty":-5.16682,"median":-3.600179,"eighty":-1.172887,"marketCap":73538409},{"date":"2026-04-17","current":-1.098674,"twenty":-5.140003,"median":-3.556109,"eighty":-1.163625,"marketCap":81431531},{"date":"2026-04-24","current":-1.047345,"twenty":-5.133171,"median":-3.450357,"eighty":-1.14771,"marketCap":77627144},{"date":"2026-05-01","current":-1.068115,"twenty":-5.124727,"median":-2.847414,"eighty":-1.126799,"marketCap":79166548},{"date":"2026-05-08","current":-1.219456,"twenty":-5.106312,"median":-2.618312,"eighty":-1.12201,"marketCap":90383607},{"date":"2026-05-15","current":-0.740696,"twenty":-5.090528,"median":-2.530202,"eighty":-1.115819,"marketCap":54898873},{"date":"2026-05-22","current":-0.73998,"twenty":-5.090528,"median":-2.500488,"eighty":-1.110669,"marketCap":51820065},{"date":"2026-05-29","current":-0.682434,"twenty":-5.087897,"median":-2.487396,"eighty":-1.099177,"marketCap":47790160},{"date":"2026-06-05","current":-0.718278,"twenty":-5.076713,"median":-2.474305,"eighty":-1.090075,"marketCap":50300271},{"date":"2026-06-12","current":-0.665632,"twenty":-5.066838,"median":-2.474305,"eighty":-1.075368,"marketCap":46613546},{"date":"2026-06-18","current":-0.64813,"twenty":-5.037912,"median":-2.474305,"eighty":-1.068115,"marketCap":45387906},{"date":"2026-06-26","current":-0.783665,"twenty":-5.034735,"median":-2.461213,"eighty":-1.059407,"marketCap":54879263},{"date":"2026-07-02","current":-0.825809,"twenty":-5.016231,"median":-2.448121,"eighty":-1.056783,"marketCap":57830604},{"date":"2026-07-10","current":-0.814468,"twenty":-4.999522,"median":-2.448121,"eighty":-1.048403,"marketCap":57036390},{"date":"2026-07-17","current":-0.722338,"twenty":-4.987538,"median":-2.441575,"eighty":-1.042823,"marketCap":50584620},{"date":"2026-07-24","current":-0.697415,"twenty":-4.985297,"median":-2.431359,"eighty":-1.025832,"marketCap":48839308},{"date":"2026-07-31","current":-0.672073,"twenty":-4.975365,"median":-2.421938,"eighty":-1.016915,"marketCap":47064581},{"date":"2026-08-07","current":-0.702876,"twenty":-4.962891,"median":-2.399368,"eighty":-1.009084,"marketCap":49221708},{"date":"2026-08-14","current":-0.892041,"twenty":-4.95899,"median":-2.382664,"eighty":-0.99687,"marketCap":54242346},{"date":"2026-08-21","current":-0.811386,"twenty":-4.943205,"median":-2.373775,"eighty":-0.980779,"marketCap":49337974}],"updateTime":1787581974827},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATYR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2642431308","title":"aTyr Pharma wins Nasdaq extension to regain $1 minimum bid price compliance by Nov. 30","url":"https://stock-news.laohu8.com/highlight/detail?id=2642431308","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642431308?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:05","pubTimestamp":1780949113,"startTime":"0","endTime":"0","summary":"aTyr Pharma received a Nasdaq notice that its shares failed the $1 minimum bid-price rule under Listing Rule 5550.Nasdaq granted a second 180-day compliance period to Nov. 30, 2026; the stock must close at or above $1 for 10 straight sessions.The company flagged a reverse stock split as a potential remedy if it cannot regain compliance through trading performance.Failure to meet the requirement by Nov. 30, 2026 would trigger a delisting notice, with an option to appeal to a Nasdaq hearings panel.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL9Q3zv1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641016965","title":"Phase 3 Efzofitimod Readout Nears: What ATYR Investors Should Watch in Pulmonary Sarcoidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2641016965","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641016965?lang=en_us&edition=fundamental","pubTime":"2026-06-05 00:31","pubTimestamp":1780590690,"startTime":"0","endTime":"0","summary":"Atyr Pharma Inc. ($ATYR) announced an update on their ongoing clinical study. The Phase 3 study “A Phase 3, Randomized, Double-Blind, Placebo-Contr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/phase-3-efzofitimod-readout-nears-what-atyr-investors-should-watch-in-pulmonary-sarcoidosis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/phase-3-efzofitimod-readout-nears-what-atyr-investors-should-watch-in-pulmonary-sarcoidosis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4211","ISBC","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639650616","title":"aTyr Pharma director Paul Schimmel acquires 100,000 common shares valued at $49,630","url":"https://stock-news.laohu8.com/highlight/detail?id=2639650616","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639650616?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:14","pubTimestamp":1779999255,"startTime":"0","endTime":"0","summary":"aTyr Pharma director Paul Schimmel bought 100,000 common shares at USD 0.5 each.Additional indirect holdings were listed at 1.41 million shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL1JPMfR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"aTyr Pharma director Paul Schimmel acquires 100,000 common shares valued at $49,630","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637821958","title":"aTyr Pharma Raised to Buy From Hold by Freedom Broker","url":"https://stock-news.laohu8.com/highlight/detail?id=2637821958","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637821958?lang=en_us&edition=fundamental","pubTime":"2026-05-21 00:38","pubTimestamp":1779295080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATYR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 20, 2026 12:38 ET (16:38 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636847779","title":"aTyr Pharma upgraded to Buy from Hold at Freedom Broker","url":"https://stock-news.laohu8.com/highlight/detail?id=2636847779","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636847779?lang=en_us&edition=fundamental","pubTime":"2026-05-20 21:00","pubTimestamp":1779282012,"startTime":"0","endTime":"0","summary":"Freedom Broker upgraded aTyr Pharma (ATYR) to Buy from Hold with a price target of $3.50, up from $1. The firm says much of the uncertainty followi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atyr-pharma-upgraded-to-buy-from-hold-at-freedom-broker-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atyr-pharma-upgraded-to-buy-from-hold-at-freedom-broker-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636885455","title":"RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636885455","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636885455?lang=en_us&edition=fundamental","pubTime":"2026-05-19 09:46","pubTimestamp":1779155209,"startTime":"0","endTime":"0","summary":"In a report released on May 15, Brian Abrahams from RBC Capital maintained a Hold rating on aTyr Pharma, with a price target of $1.00. The company’...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-atyr-pharma-atyr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-atyr-pharma-atyr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078312","title":"Wells Fargo Sticks to Their Hold Rating for aTyr Pharma (ATYR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078312","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636078312?lang=en_us&edition=fundamental","pubTime":"2026-05-18 19:36","pubTimestamp":1779104204,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Derek Archila maintained a Hold rating on aTyr Pharma today and set a price target of $1.00. Archila covers the Healthcare sect...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-their-hold-rating-for-atyr-pharma-atyr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-their-hold-rating-for-atyr-pharma-atyr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635031793","title":"aTyr Pharma Inc options imply 30.5% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2635031793","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635031793?lang=en_us&edition=fundamental","pubTime":"2026-05-16 01:57","pubTimestamp":1778867822,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in aTyr Pharma (ATYR) Inc is normal with calls leading puts 142:1. Implied volatility suggests the market is anticipati...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atyr-pharma-inc-options-imply-30-5-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atyr-pharma-inc-options-imply-30-5-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635826980","title":"aTyr Pharma Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635826980","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635826980?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:43","pubTimestamp":1778849000,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc reports results for the quarter ended March 31 - Earnings SummaryaTyr Pharma Inc ATYR.OQ reported a quarterly adjusted loss of 11 cents per share for the quarter ended March 31, higher","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S1BQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635084659","title":"aTyr Pharma Q1 EPS $(0.11) Beats $(0.14) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635084659","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635084659?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:17","pubTimestamp":1778847473,"startTime":"0","endTime":"0","summary":"aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 35.29 percent increase over losses of $(0.17) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52593660/atyr-pharma-q1-eps-0-11-beats-0-14-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635780081","title":"aTyr Pharma plans Phase 3 efzofitimod trial in restrictive pulmonary sarcoidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2635780081","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635780081?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:04","pubTimestamp":1778846682,"startTime":"0","endTime":"0","summary":"aTyr Pharma outlined plans in first-quarter 2026 update to launch a new global Phase 3 study of efzofitimod in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, targeting an IND submission in June 2026.FDA feedback in a Type C meeting set a new development path following prior Phase 3 EFZO-FIT results, which were already reviewed with regulators.Trial aims to show efzofitimod can preserve lung function while improving patient-reported breathing-related health status, with dosing set once every three weeks over 54 weeks.Study design calls for up to 372 patients on stable background therapy, positioning the program for a renewed late-stage readout in a high-unmet-need interstitial lung disease segment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fina","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL5dn8NR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635108190","title":"aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635108190","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635108190?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:00","pubTimestamp":1778846402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA8MHSGW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635587927","title":"aTyr Pharma plans Phase 3 pulmonary sarcoidosis trial of efzofitimod with FVC endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2635587927","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635587927?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:07","pubTimestamp":1778702858,"startTime":"0","endTime":"0","summary":"aTyr Pharma mapped a new Phase 3 trial plan for efzofitimod in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, shifting strategy following an FDA Type C meeting that reviewed results from Phase 3 EFZO-FIT.EFZO-FIT results were already presented to FDA; next pivotal study will test whether efzofitimod can preserve lung function and improve patient-reported breathing-related well-being versus placebo in a more defined, higher-severity population.Company plans to submit an IND in June 2026; trial design calls for a 54-week, global, randomized, double-blind study of intravenous 5.0 mg/kg dosing every three weeks.Planned study size up to 372 patients; primary readout set for week 48, with a patient-reported outcome positioned as a key secondary endpoint.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL61LWxl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635000172","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2635000172","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635000172?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:00","pubTimestamp":1778666400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Copa Hldgs A                                     1Q      4.14    4:30 PM. ·FLEX LNG Ltd                                    1Q       .36    1:00 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHVS","BBWI","BTBT","BTGO","CLNN","BEEM","ALT","ATS","BIRK","CBUS","CING","CLBT","CCAP","CPA","BHST","AUTL","PYPD","CCCC","GOOS","CAAP","BGSI","BTDR","ALLO","CSIQ","CLPT","BWAY","ATYR","BLSH","BZAI","BEAT","CSCO","BN","ATAT","ARX","AQST","AEBI","ACOG","CSWC","BABA","DERM","KARO","CELC","CMPS","ABEO","AYTU","AVAH","AMAT","BOOT","CNTB","AKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634215767","title":"Piper Sandler Sticks to Their Buy Rating for aTyr Pharma (ATYR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634215767","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634215767?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:30","pubTimestamp":1778585455,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on aTyr Pharma today and set a price target of $20.00. According to TipRanks, Rahimi i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-atyr-pharma-atyr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-atyr-pharma-atyr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634023210","title":"aTyr Pharma plans June 2026 IND for new Phase 3 efzofitimod sarcoidosis trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2634023210","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634023210?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:04","pubTimestamp":1778529847,"startTime":"0","endTime":"0","summary":"aTyr Pharma mapped out a new global Phase 3 trial for efzofitimod in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, following FDA Type C meeting minutes reviewing prior Phase 3 EFZO-FIT results.EFZO-FIT results have already been presented to FDA; next pivotal study will test whether efzofitimod can slow loss of lung function while improving patient-reported symptoms, without citing detailed measurements.IND submission targeted for June 2026; trial designed as randomized, double-blind, placebo-controlled study enrolling up to 372 patients, with dosing moved to every three weeks to increase drug exposure.Primary readout will focus on lung function change at week 48; key secondary will assess symptom and quality-of-life improvement, with study duration set at 54 weeks.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL9VnMG4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU0314104364.USD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","BK4139","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4585","BK4588","ATYR","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634522232","title":"aTyr Pharma Inc - Primary Endpoint Will Be Change in Fvc at Week 48; Key Secondary Endpoint Will Be Change From Baseline in Ksq-Lung Score","url":"https://stock-news.laohu8.com/highlight/detail?id=2634522232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634522232?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:01","pubTimestamp":1778529660,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUA1WXQBX:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232571","title":"aTyr Pharma Inc - Dosing Frequency of 5.0 Mg/Kg Efzofitimod or Placebo Increased to Every Three Weeks in Next Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232571","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232571?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:01","pubTimestamp":1778529660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUA1WXQBX:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634223236","title":"aTyr Pharma Inc: to Continue Development of Efzofitimod in Pulmonary Sarcoidosis Incorporating FDA Feedback","url":"https://stock-news.laohu8.com/highlight/detail?id=2634223236","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634223236?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:01","pubTimestamp":1778529660,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nTUA1WXQBX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634229469","title":"aTyr Pharma Inc options imply 14.1% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2634229469","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634229469?lang=en_us&edition=fundamental","pubTime":"2026-05-09 02:51","pubTimestamp":1778266265,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in aTyr Pharma (ATYR) Inc is normal with calls leading puts 22:1. Implied volatility suggests the market is anticipatin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atyr-pharma-inc-options-imply-14-1-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atyr-pharma-inc-options-imply-14-1-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":52,"code":"91000000","status":"200"}]}}